We show that molecular testing of blood on treatment day 4, by either qPCR assessment of WT1 expression or DNA sequencing for common MDS/AML variants, is not predictive of clinical response to intensive cytotoxic therapy in AML. This evidence concerns the gene WT1 and myelodysplastic syndrome.